| . | Stage 1 N = 0 (0%) . | Stage 2 N = 27 (15.7%) . | Stage 3 N = 80 (46.5%) . | Stage 4 N = 62 (36%) . | Stage 5 N = 3 (1.7%) . | P-value . |
|---|---|---|---|---|---|---|
| Surgery | ||||||
| TVR | 7 (5.4%) | 67 (51.9%) | 52 (40.3%) | 3 (2.3%) | ||
| TVr | 20 (46.5%) | 13 (30.2%) | 10 (23.3%) | 0 (0%) | ||
| Preop characteristics | ||||||
| Age (years) | 48 (28–64) | 68 (58–75) | 70 (63–76) | 75 (68–79) | <0.001 | |
| Sex (Female) | 13 (48%) | 51 (64%) | 46 (74%) | 2 (67%) | 0.107 | |
| NYHA III–IV | 5 (19%) | 44 (55.5%) | 55 (89%) | 3 (100%) | <0.001 | |
| AFib | 7 (26%) | 53 (66%) | 54 (87%) | 2 (67%) | <0.001 | |
| CKD | 0 (0%) | 15 (19%) | 21 (34%) | 3 (100%) | <0.001 | |
| eGFR (ml/min) | 94 (77–138) | 66 (49–90) | 52 (37–69) | 28 (27.6–28) | <0.001 | |
| Bilirubin (mg/dl) | 0.8 (0.5–1.3) | 0.9 (0.6–1.5) | 1.1 (0.8–1.4) | 0.7 (0.3–1) | 0.083 | |
| Albumin | 62 (59–63) | 58 (54–61) | 57 (52–59) | 54 (45–58) | <0.001 | |
| AST (U/l) | 22 (18–29) | 27 (22–38) | 30 (24–39) | 19 (15–26) | 0.004 | |
| ALT (U/l) | 26 (17–29) | 22 (18–29) | 22 (14–27) | 12 (9–14) | 0.060 | |
| Ascites | 0 (0%) | 3 (3.8%) | 31 (50%) | 3 (100%) | <0.001 | |
| Diuretics dose (mg) | 0 (0–16.25) | 25 (0–50) | 100 (50–175) | 375 (125–500) | <0.001 | |
| RHF hospitalization | 0 (0%) | 8 (10%) | 48 (77%) | 3 (100%) | <0.001 | |
| REDO | 7 (26%) | 42 (53%) | 47 (76%) | 3 (100%) | <0.001 | |
| Preop TOE parameters | ||||||
| LVEDD (mm) | 45.3 ± 6.18 | 46.6 ± 5.17 | 48.5 ± 7.57 | 59 ± 10.54 | <0.001 | |
| LVEF (%) | 60 (60–63) | 60 (57–62) | 55 (51–60) | 60 (50–60) | 0.003 | |
| sPAP (mmHg) | 35 (30–40) | 40 (35–50) | 40 (35–50) | 43 (38–50) | <0.001 | |
| TAPSE (mm) | 26.2 ± 3.71 | 21.4 ± 5.56 | 18 ± 4.54 | 17 | 0.001 | |
| TDI (m/s) | 12 (10–16) | 11 (10–13) | 9.4 (8–10) | NA | 0.001 |
| . | Stage 1 N = 0 (0%) . | Stage 2 N = 27 (15.7%) . | Stage 3 N = 80 (46.5%) . | Stage 4 N = 62 (36%) . | Stage 5 N = 3 (1.7%) . | P-value . |
|---|---|---|---|---|---|---|
| Surgery | ||||||
| TVR | 7 (5.4%) | 67 (51.9%) | 52 (40.3%) | 3 (2.3%) | ||
| TVr | 20 (46.5%) | 13 (30.2%) | 10 (23.3%) | 0 (0%) | ||
| Preop characteristics | ||||||
| Age (years) | 48 (28–64) | 68 (58–75) | 70 (63–76) | 75 (68–79) | <0.001 | |
| Sex (Female) | 13 (48%) | 51 (64%) | 46 (74%) | 2 (67%) | 0.107 | |
| NYHA III–IV | 5 (19%) | 44 (55.5%) | 55 (89%) | 3 (100%) | <0.001 | |
| AFib | 7 (26%) | 53 (66%) | 54 (87%) | 2 (67%) | <0.001 | |
| CKD | 0 (0%) | 15 (19%) | 21 (34%) | 3 (100%) | <0.001 | |
| eGFR (ml/min) | 94 (77–138) | 66 (49–90) | 52 (37–69) | 28 (27.6–28) | <0.001 | |
| Bilirubin (mg/dl) | 0.8 (0.5–1.3) | 0.9 (0.6–1.5) | 1.1 (0.8–1.4) | 0.7 (0.3–1) | 0.083 | |
| Albumin | 62 (59–63) | 58 (54–61) | 57 (52–59) | 54 (45–58) | <0.001 | |
| AST (U/l) | 22 (18–29) | 27 (22–38) | 30 (24–39) | 19 (15–26) | 0.004 | |
| ALT (U/l) | 26 (17–29) | 22 (18–29) | 22 (14–27) | 12 (9–14) | 0.060 | |
| Ascites | 0 (0%) | 3 (3.8%) | 31 (50%) | 3 (100%) | <0.001 | |
| Diuretics dose (mg) | 0 (0–16.25) | 25 (0–50) | 100 (50–175) | 375 (125–500) | <0.001 | |
| RHF hospitalization | 0 (0%) | 8 (10%) | 48 (77%) | 3 (100%) | <0.001 | |
| REDO | 7 (26%) | 42 (53%) | 47 (76%) | 3 (100%) | <0.001 | |
| Preop TOE parameters | ||||||
| LVEDD (mm) | 45.3 ± 6.18 | 46.6 ± 5.17 | 48.5 ± 7.57 | 59 ± 10.54 | <0.001 | |
| LVEF (%) | 60 (60–63) | 60 (57–62) | 55 (51–60) | 60 (50–60) | 0.003 | |
| sPAP (mmHg) | 35 (30–40) | 40 (35–50) | 40 (35–50) | 43 (38–50) | <0.001 | |
| TAPSE (mm) | 26.2 ± 3.71 | 21.4 ± 5.56 | 18 ± 4.54 | 17 | 0.001 | |
| TDI (m/s) | 12 (10–16) | 11 (10–13) | 9.4 (8–10) | NA | 0.001 |
AFib: atrial fibrillation; ALT: alanine aminotransferase; AST: aspartate aminotransferase; CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate; LVEDD: left ventricular end-diastolic diameter; LVEF: left ventricular ejection fraction; NYHA: New York Heart Association; preop: preoperative; RHF: right heart failure; sPAP: systolic pulmonary artery pressure; TAPSE: tricuspid annular plane systolic excursion; TDI: tissue Doppler imaging; TOE: transoesophageal echocardiography; TVr: tricuspid valve repair; TVR: tricuspid valve replacement.
| . | Stage 1 N = 0 (0%) . | Stage 2 N = 27 (15.7%) . | Stage 3 N = 80 (46.5%) . | Stage 4 N = 62 (36%) . | Stage 5 N = 3 (1.7%) . | P-value . |
|---|---|---|---|---|---|---|
| Surgery | ||||||
| TVR | 7 (5.4%) | 67 (51.9%) | 52 (40.3%) | 3 (2.3%) | ||
| TVr | 20 (46.5%) | 13 (30.2%) | 10 (23.3%) | 0 (0%) | ||
| Preop characteristics | ||||||
| Age (years) | 48 (28–64) | 68 (58–75) | 70 (63–76) | 75 (68–79) | <0.001 | |
| Sex (Female) | 13 (48%) | 51 (64%) | 46 (74%) | 2 (67%) | 0.107 | |
| NYHA III–IV | 5 (19%) | 44 (55.5%) | 55 (89%) | 3 (100%) | <0.001 | |
| AFib | 7 (26%) | 53 (66%) | 54 (87%) | 2 (67%) | <0.001 | |
| CKD | 0 (0%) | 15 (19%) | 21 (34%) | 3 (100%) | <0.001 | |
| eGFR (ml/min) | 94 (77–138) | 66 (49–90) | 52 (37–69) | 28 (27.6–28) | <0.001 | |
| Bilirubin (mg/dl) | 0.8 (0.5–1.3) | 0.9 (0.6–1.5) | 1.1 (0.8–1.4) | 0.7 (0.3–1) | 0.083 | |
| Albumin | 62 (59–63) | 58 (54–61) | 57 (52–59) | 54 (45–58) | <0.001 | |
| AST (U/l) | 22 (18–29) | 27 (22–38) | 30 (24–39) | 19 (15–26) | 0.004 | |
| ALT (U/l) | 26 (17–29) | 22 (18–29) | 22 (14–27) | 12 (9–14) | 0.060 | |
| Ascites | 0 (0%) | 3 (3.8%) | 31 (50%) | 3 (100%) | <0.001 | |
| Diuretics dose (mg) | 0 (0–16.25) | 25 (0–50) | 100 (50–175) | 375 (125–500) | <0.001 | |
| RHF hospitalization | 0 (0%) | 8 (10%) | 48 (77%) | 3 (100%) | <0.001 | |
| REDO | 7 (26%) | 42 (53%) | 47 (76%) | 3 (100%) | <0.001 | |
| Preop TOE parameters | ||||||
| LVEDD (mm) | 45.3 ± 6.18 | 46.6 ± 5.17 | 48.5 ± 7.57 | 59 ± 10.54 | <0.001 | |
| LVEF (%) | 60 (60–63) | 60 (57–62) | 55 (51–60) | 60 (50–60) | 0.003 | |
| sPAP (mmHg) | 35 (30–40) | 40 (35–50) | 40 (35–50) | 43 (38–50) | <0.001 | |
| TAPSE (mm) | 26.2 ± 3.71 | 21.4 ± 5.56 | 18 ± 4.54 | 17 | 0.001 | |
| TDI (m/s) | 12 (10–16) | 11 (10–13) | 9.4 (8–10) | NA | 0.001 |
| . | Stage 1 N = 0 (0%) . | Stage 2 N = 27 (15.7%) . | Stage 3 N = 80 (46.5%) . | Stage 4 N = 62 (36%) . | Stage 5 N = 3 (1.7%) . | P-value . |
|---|---|---|---|---|---|---|
| Surgery | ||||||
| TVR | 7 (5.4%) | 67 (51.9%) | 52 (40.3%) | 3 (2.3%) | ||
| TVr | 20 (46.5%) | 13 (30.2%) | 10 (23.3%) | 0 (0%) | ||
| Preop characteristics | ||||||
| Age (years) | 48 (28–64) | 68 (58–75) | 70 (63–76) | 75 (68–79) | <0.001 | |
| Sex (Female) | 13 (48%) | 51 (64%) | 46 (74%) | 2 (67%) | 0.107 | |
| NYHA III–IV | 5 (19%) | 44 (55.5%) | 55 (89%) | 3 (100%) | <0.001 | |
| AFib | 7 (26%) | 53 (66%) | 54 (87%) | 2 (67%) | <0.001 | |
| CKD | 0 (0%) | 15 (19%) | 21 (34%) | 3 (100%) | <0.001 | |
| eGFR (ml/min) | 94 (77–138) | 66 (49–90) | 52 (37–69) | 28 (27.6–28) | <0.001 | |
| Bilirubin (mg/dl) | 0.8 (0.5–1.3) | 0.9 (0.6–1.5) | 1.1 (0.8–1.4) | 0.7 (0.3–1) | 0.083 | |
| Albumin | 62 (59–63) | 58 (54–61) | 57 (52–59) | 54 (45–58) | <0.001 | |
| AST (U/l) | 22 (18–29) | 27 (22–38) | 30 (24–39) | 19 (15–26) | 0.004 | |
| ALT (U/l) | 26 (17–29) | 22 (18–29) | 22 (14–27) | 12 (9–14) | 0.060 | |
| Ascites | 0 (0%) | 3 (3.8%) | 31 (50%) | 3 (100%) | <0.001 | |
| Diuretics dose (mg) | 0 (0–16.25) | 25 (0–50) | 100 (50–175) | 375 (125–500) | <0.001 | |
| RHF hospitalization | 0 (0%) | 8 (10%) | 48 (77%) | 3 (100%) | <0.001 | |
| REDO | 7 (26%) | 42 (53%) | 47 (76%) | 3 (100%) | <0.001 | |
| Preop TOE parameters | ||||||
| LVEDD (mm) | 45.3 ± 6.18 | 46.6 ± 5.17 | 48.5 ± 7.57 | 59 ± 10.54 | <0.001 | |
| LVEF (%) | 60 (60–63) | 60 (57–62) | 55 (51–60) | 60 (50–60) | 0.003 | |
| sPAP (mmHg) | 35 (30–40) | 40 (35–50) | 40 (35–50) | 43 (38–50) | <0.001 | |
| TAPSE (mm) | 26.2 ± 3.71 | 21.4 ± 5.56 | 18 ± 4.54 | 17 | 0.001 | |
| TDI (m/s) | 12 (10–16) | 11 (10–13) | 9.4 (8–10) | NA | 0.001 |
AFib: atrial fibrillation; ALT: alanine aminotransferase; AST: aspartate aminotransferase; CKD: chronic kidney disease; eGFR: estimated glomerular filtration rate; LVEDD: left ventricular end-diastolic diameter; LVEF: left ventricular ejection fraction; NYHA: New York Heart Association; preop: preoperative; RHF: right heart failure; sPAP: systolic pulmonary artery pressure; TAPSE: tricuspid annular plane systolic excursion; TDI: tissue Doppler imaging; TOE: transoesophageal echocardiography; TVr: tricuspid valve repair; TVR: tricuspid valve replacement.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
